Information  X 
Enter a valid email address

Puretech Health PLC Ord 1P (PRTC)

Related News

21-Jun-2022 02:24 PM

IN BRIEF: PureTech Health's Gelesis wins $15 million Plenity order

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Investee Gelesis Holdings Inc receives another $15 million pre-order for its weight management aid product Plenity from its distribution partner, New-York based tele
14-Jun-2022 04:54 PM

IN BRIEF: PureTech achieves availability milestone for LYT-300 study

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Announces results from phase two study of LYT-100-COV on patients with post acute or long Covid with respiratory complications. No treatment effect was observed
05-May-2022 11:18 AM

IN BRIEF: PureTech shares rise as unveils $50 million share buyback

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Approves share buyback of up to $50 million. Programme follows ‘follows consultation with shareholders and is consistent with PureTech's capital allocatio
04-May-2022 01:35 PM

PureTech entity Gelesis reports positive data for weight loss drug

Boston-based biotechnology company PureTech Health PLC's founded entity Gelesis Holdings Inc said on Wednesday that its weight loss drug showed positive responses in adults in clinical trials. Gelesis, formerly Gelesis Inc, recently liste
21-Jul-2021 01:28 PM

Pfizer make $25 million investment in PureTech's Vedanta Biosciences

Pharmaceutical company Pfizer has invested £25 million in Vedanta Biosciences as part of a funding round that will advance its pipeline of defined bacterial consortia work. Vedanta Biosciences, a clinical-stage microbiome company developing a new c
26-May-2021 01:15 PM

Akili Interative secures $160 million in financing

PureTech Health has announced that its founded entity, Akili Interactive, has secured $160 million of combined equity and debt financing. The financing included a $110 million Series D equity financing round led by Neuberger Berman Funds and joined by n
12-May-2021 04:09 PM

PureTech forms clinical advisory board

PureTech Health has formed a Clinical Advisory Board for idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILDs). Comprised of physicians and researchers with deep expertise in the clinical development of
18-Mar-2021 08:00 AM

PureTech's COO to retire

The chief operating office of clinical-stage biotherapeutics company, PureTech Health, is to retire from the role on May 17, 2021. Stephen Muniz will retire as the company?s COO and corporate secretary, with his responsibilities to be taken on by Bharat
05-Jan-2021 09:26 AM

PureTech appoints BMO's George Farmer as CFO

PureTech Health a clinical-stage biotherapeutics company, has announced that George Farmer, Ph.D., has been appointed chief financial officer. The firm is dedicated to discovering, developing and commercializing highly differentiated medicines for devasta
24-Nov-2020 01:45 PM

Vedanta Biosciences appoints Karuna Therapeutics' Ignelzi to board of directors

Clinical-stage company Vedanta Biosciences has announced the appointment of Troy Ignelzi as an independent member to its board of directors. Vedanta is developing a new category of therapies for immune-mediated diseases based on rationally-defined conso
11-Nov-2020 01:11 PM

PureTech Health subsid licenses clinical-stage cancer treatment

PureTech Heath founded entity Vor has entered an exclusive licensing agreement with the National Cancer Institute. This agreement covers the group's intellectual property related to clinical stage cancer treatments of anti-CD33 chimeric antigen rec
27-Aug-2020 07:57 AM

PureTech income soars after regulatory approvals and subsidiary sales

Biotechnology company PureTech Health generated $245m of cash in the first half of 2020 through the sales of stakes in subsidiaries. Its H1 income after tax of $123.7m was nearly four times the level recorded in the first half of 2019. The company cited
29-Jul-2020 09:20 AM

Broker Forecast - Liberum Capital issues a broker note on PureTech Health Plc

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 490p (from 450p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
09-Apr-2020 09:37 AM

PureTech Health boosts wholly owned pipeline in 2019; says Covid-19 may eventually impact timelines

Clinical stage biotherapeutics company PureTech Health has reported a strong capital base with $321.5m in pro-forma cash in its annual results to 31 December 2019 and confirmed the growth of its wholly owned internal pipeline. The company announced PureT
24-Jan-2020 10:20 AM

Broker Forecast - Liberum Capital issues a broker note on PureTech Health Plc

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 450p (from 420p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
23-Jan-2020 07:15 AM

PureTech sells minority shares in Karuna

Clinical stage biotech company, PureTech Health, has announced it has sold 2.1 million shares of its affiliate, Karuna Therapeutics. The cash sale has generated approximately $200 million which PureTech Health intends to use to fund its operations and g
13-Jan-2020 11:20 AM

Broker Forecast - Liberum Capital issues a broker note on PureTech Health Plc

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and cut its price target to 420p (from 450p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
22-Nov-2019 08:10 AM

Broker Forecast - Peel Hunt issues a broker note on PureTech Health Plc

Peel Hunt today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 460p (from 380p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
20-Nov-2019 08:30 AM

Broker Forecast - Liberum Capital issues a broker note on PureTech Health Plc

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 450p (from 300p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
27-Aug-2019 08:10 AM

Broker Forecast - Liberum Capital issues a broker note on PureTech Health Plc

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 347p (from 336p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
27-Aug-2019 07:22 AM

PureTech Health losses widen on higher R&D spending, tax charge

Clinical stage biotechnology company PureTech Health booked a first-half loss after a gain in the value of its investments was offset by a higher tax charge and steeper R&D spending. Net losses for the six months through June amounted to $14.0m, compared
19-Jul-2019 08:10 AM

Broker Forecast - Peel Hunt issues a broker note on PureTech Health Plc

Peel Hunt today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 380p (from 344p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
02-Jul-2019 10:50 AM

Broker Forecast - Liberum Capital issues a broker note on PureTech Health Plc

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 336p (from 308p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
25-Apr-2019 09:31 AM

PureTech Health affiliate Gelesis receives $10.6m grant for first product

Biopharmaceutical company PureTech Health has announced that its affiliate Gelesis has received a $10.6m grant to support the commercial manufacturing of its first product, Plenity. The company said it hoped to launch Plenity in the United States in the
24-Apr-2019 09:31 AM

PureTech Health posts annual loss owing to treatment development spending

PureTech Health, which develops treatments for 'dysfunctions of the brain-immune-gut axis', booked an full-year loss as it ramped up R&D spending. Pre-tax losses for the year through December amounted to $68.4m, compared to losses of $70.7m on-

a d v e r t i s e m e n t